Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients
- 30 September 1991
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (9) , 1081-1083
- https://doi.org/10.1016/0277-5379(91)90296-p
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomitingCancer Chemotherapy and Pharmacology, 1989
- A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic responseCancer Chemotherapy and Pharmacology, 1989
- Antiemetic therapy for chemotherapy-induced vomiting: Metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine aloneThe Journal of Pediatrics, 1989
- Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine.Journal of Clinical Oncology, 1986
- Frequency of extrasystoles in healthy male employees.Heart, 1986
- Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.Journal of Clinical Oncology, 1985
- Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapyThe Journal of Pediatrics, 1984
- 24-hour electrocardiographic study of heart rate and rhythm patterns in population of healthy children.Heart, 1981
- Management of Nausea and Vomiting in the Cancer PatientJAMA, 1981